abbreviatioNs ACTH = adrenocorticotropic hormone; CD = Cushing disease; CRH = corticotropin-releasing hormone; hrPET = high-resolution PET; IPSS = inferior petrosal sinus sampling; SE = spin echo; SPGR = spoiled gradient recalled; SUV = standardized uptake value; SUV Avg = average SUV; SUV Max = maximum SUV. results Ten patients (7 females and 3 males) were included (mean age 30.8 ± 19.3 years; range 11-59 years). MRI revealed a pituitary adenoma in 4 patients (40% of patients) on SE and 7 patients (70%) on SPGR sequences.
B
iochemical remission after transsphenoidal surgery in Cushing disease (CD) is influenced by the ability to visualize a pituitary adenoma on preoperative imaging. Currently, MRI is the gold standard for detecting pituitary microadenomas. Nevertheless, modern pituitary MRI sequences fail to detect a pituitary adenoma in approximately 40% of CD cases due to small tumor size and/ or poor MRI contrast-to-noise ratio at the sella-sphenoid interface. 8, 11 When adenomas are visible on preoperative imaging, remission rates approaching 90%-100% have been reported. 15, 16 When adenomas are not detected on preoperative MRI, remission rates can decrease to 50%-60% in CD. 11, 15, 17 Standard spin echo (SE) MRI sequences (pre-and postcontrast administration) have been and are currently used to image the pituitary gland for adenomas in CD. Using SE MRI, approximately 50% of adenomas in CD can be detected using preoperative postcontrast MRI studies.
14 Since 2003, the spoiled gradient recalled (SPGR) MRI sequence (pre-and postcontrast administration) has been used to best enhance detection of pituitary adenomas in CD. 2, 10, 11 While SPGR MRI has increased detection of pituitary adenomas in CD (a 10%-15% increase in sensitivity in CD adenoma detection), a large portion of pituitary adenomas in CD remain undetected on MRI before resection. 8, 11, 14 To enhance detection of pituitary adenomas in patients with CD undergoing SE and/or SPGR MRI, investigators have used standard resolution (approximately 6-mm resolution) 18 
F-fluorodeoxyglucose (

18
F-FDG) PET imaging.
Data from these MRI and PET studies revealed that 18 F-FDG PET is complementary to SE MRI in detecting pituitary adenomas not detected on preoperative MRI in 25% of CD cases. 1, 4 Recently, technological advances have led to development of high-resolution PET (hrPET) using a high-resolution research tomograph scanner.
18 These scanners have a 2-mm resolution. 3 These advances suggest that hrPET scanners may be used to detect small biologically active adenomas in CD via 18 F-FDG uptake.
1,4
Based on improvements in both MRI and PET as defined above, the combination of these 2 modalities may provide an opportunity to enhance detection of CD-associated pituitary adenomas. To assess the sensitivity of these imaging techniques for detection of CD-associated pituitary adenomas (alone and in a complementary fashion), we prospectively compared high-resolution MRI (SE and SPGR sequences) with 
methods patients
Patients with CD were enrolled in a clinical trial (registration no. NCT01459237) (clinicaltrials.gov) conducted at the National Institute of Neurological Diseases and Stroke (NINDS) (12-N-0007) to prospectively evaluate the use of 18 F-FDG hrPET for CD. All patients or guardians (in the case of minors) signed informed consent.
diagnosis of cd
To distinguish between adrenocorticotropic hormone (ACTH)-dependent causes (either ectopic or pituitary) of hypercortisolism, patients underwent biochemical evaluation including high-dose dexamethasone testing, corticotropin-releasing hormone (CRH) stimulation testing, and MRI of the pituitary. Patients with high-dose dexamethasone suppression of cortisol, CRH-induced elevation of ACTH and cortisol, as well as MRI evidence of a pituitary adenoma were given a diagnosis of CD. Patients with negative findings on MRI or indefinite endocrinological evaluation underwent inferior petrosal sinus sampling (IPSS) to confirm or exclude a pituitary source of ACTH secretion. 13 
mri of the pituitary gland
All patients underwent MRI of the pituitary gland before resection. MRI sequences included 3-mm SE sequences in coronal and sagittal orientation, as well as 1-mm 3D gradient echo (spoiled gradient or SPGR) sequence, as described previously.
14 Coronal T1-weighted SE scans were obtained using the following parameters: TR 400 msec, TE 9 msec, and 12-cm FOV. Contiguous 3-mm-thick slices were obtained. SPGR scans were performed using the following parameters: TR 9.6 msec, TE 2.3 msec, and 12-cm FOV. Contiguous 1-mm-thick coronal slices were obtained for SPGR sequences. MRI findings were assessed by a neuroradiologist before surgery for the presence of an adenoma. Adenoma volume was assessed by a formula calculating ellipsoid volume of brain tumors (volume = [maximal mediolateral dimension × maximal anteroposterior dimension × maximal vertical dimension]/2).
19
F-Fdg hrpet protocol
PET imaging was performed using a high-resolution research tomography scanner (Siemens AG). Subjects were asked to fast (except water) for at least 6 hours prior to the imaging session. Commercially manufactured 18 F-FDG was injected intravenously over a period of approximately 1 minute. The 18 F-FDG dose was standardized at 10 mCi in patients who were 18 years and older. For patients younger than 18 years, the dose was calculated at 0.08 mCi/kg. The subjects rested quietly in a dark room for approximately 30 minutes after 18 F-FDG administration. During the scan, a cap with small light reflectors was placed on the subject's head to monitor head position with a Polaris Vicra head tracking system (Northern Digital Inc.). Information about head movement was used in the image reconstruction process to reduce the blurring effect of head movement on the PET images. After the patient was positioned in the scanner, a transmission scan was obtained with a 137 Cesium rotating pin source to correct emission images for attenuation. Then a PET emission scan of the brain was obtained in 3D mode starting about 50 minutes after 
surgical procedure
All patients underwent a standard sublabial transsphe-noidal approach for pituitary adenoma resection, as described previously. 9 Briefly, wide bony removal was performed at the sellar face and sellar floor until the cavernous sinuses were visualized. Once dura overlying the pituitary gland was opened, the exposed pituitary gland was inspected for the presence of tumor. The pituitary capsule was incised adjacent to the expected adenoma location. The pituitary pseudocapsule was developed to complete selective adenectomy. When cavernous sinus invasion was suspected, the involved medial wall of the cavernous sinus was removed.
histopathology
Routine H&E staining was performed to evaluate the surgical specimens, as well as reticulin staining. ACTH immunostaining was performed to confirm the diagnosis of corticotroph adenoma.
statistical analysis
An unpaired t-test was used to detect a difference between the means. Fisher's exact test was used for analysis of contingency tables. Pearson correlation coefficients were calculated when generating correlation matrices for continuous variables. The McNemar test was used to compare sensitivities of diagnostic tests. Statistical significance was set at p ≤ 0.05.
results patients
Ten consecutive patients (7 females and 3 males) were included (mean age 30.8 ± 19.3 years [SD]; range 11-59 years) ( Table 1 ). All patients were diagnosed with CD on the basis of clinical and biochemical criteria. While 1 patient presented with recurrent CD, 9 patients were diagnosed with new-onset CD (Table 1 ). All 10 patients underwent MRI of the pituitary gland and 18 F-FDG hrPET imaging before surgery.
imaging Findings
MRI
A pituitary adenoma was visible in 4 patients using postcontrast SE MRI, and an adenoma was visible in 7 patients using SPGR MRI sequences. All pituitary adenomas that were detected by SE MRI were also detected using SPGR MRI. Adenoma location on MRI corresponded with the surgical location of the adenoma in every case. There was no association between MRI adenoma detection and biochemical findings.
MRI Compared With
18 F-FDG hrPET Imaging Three adenomas were detected on SPGR MRI but not on 18 F-FDG hrPET.
18
F-FDG hrPET did not detect any adenomas that SPGR MRI did not detect. All adenomas detected on SE MRI were detected by 18 F-FDG hrPET. Furthermore, 18 F-FDG hrPET detected 2 adenomas that were not detected by SE MRI (Table 1) . These 2 adenomas were 3 and 5 mm in diameter (Fig. 1) . Adenoma location on 18 F-FDG hrPET-positive imaging corresponded with the surgical location of the adenoma.
F-Fdg hrpet imaging
Increased SUVs corresponding to an adenoma were detected in 4 patients. The maximum SUV (SUV Max ) in 18 F-FDG hrPET-positive adenoma ranged from 6.0 to 12.8 (mean 9.5 ± 1.6) ( Table 2 ). The average SUV (SUV Avg ) in the sella ranged from 2.3 to 4.0 (mean 3.1 ± 0.4) in (Fig. 2) . There was no association between the IPSS central-to-peripheral ratio and F-FDG hrPET-negative tumors had an increase in ACTH after stimulation greater than 180% (Fig. 3) . No association was found with cortisol response to CRH stimulation (p = 0.8) with ). Invasion of the adjacent dura was identified in 3 cases (anterior sella dura in 1 case and medial cavernous sinus wall in 2 cases).
Clinical Results
All patients achieved biochemical remission after surgery. Briefly, biochemical remission was defined by postoperative morning serum cortisol and 24-hour urinary free cortisol. Patients achieved either a reduction of serum cortisol below 5 mg/dl and urinary free cortisol below the reference range (hypocortisolemia) or within the reference range (eucortisolemia).
11 Histology confirmed an ACTHpositive adenoma in all cases.
discussion mri in cd
Adoption of SPGR MRI sequences led to an increased sensitivity (80%) compared with SE MRI sequences (49%).
14 The SPGR MRI technique utilizes faster acquisition times leading to minimal movement and pulsation artifacts. Although a lower signal-to-noise ratio is reported for SPGR sequences than for SE sequences, a higher contrast-to-noise ratio is achievable. Moreover, SPGR MRI allows for 1-mm-thick sections, which can potentially permit detection of smaller adenomas.
14 Subsequently, SPGR MRI is superior for detecting smaller tumors that have a contrast difference relative to the normal pituitary gland. For these reasons, we have found that SPGR MRI provides optimal detection of pituitary adenomas in CD patients. 
Fig. 1. Images obtained in a patient in whom a hypoenhancing adenoma (arrowheads) was detected on SPGR sequences (a and b), but not on SE sequences (c and d). Corresponding 18 F-FDG hrPET images (e and F) revealed a focus of increased 18 F-FDG uptake (arrowhead).
imaging of the pituitary gland/sella has high specificity for detection of pituitary adenomas 5 and could potentially be used for detection of pituitary adenomas in this region. Specifically, these prior data suggested that 18 F-FDG PET imaging could be exploited to detect biologically (high metabolic) active CD-associated adenomas that suppress the metabolic activity of the surrounding pituitary gland.
Based on the pituitary findings from whole-body 18 F-FDG PET imaging and the biological features of CD-associated adenomas, groups have used standard resolution 18 F-FDG PET imaging in CD patients for adenoma detection. These studies found that in 25% of cases,
18
F-FDG PET imaging played a complementary role to SE MRI, detecting ACTH-secreting adenomas that were not visible on SE MRI.
1,4 Furthermore, no false-positive cases were reported with the use of 18 F-FDG PET imaging in CD in these series. 1, 4 Nevertheless, some lesions not detected using 18 F-FDG PET imaging were visualized on SE MRI, but no biological explanation for these results was established that would improve understanding of the application of the 18 F-FDG PET imaging modality.
Here, we analyzed the effectiveness of 18 F-FDG hrPET imaging (2-mm resolution) and biological factors associated with 18 F-FDG hrPET imaging positivity in patients with CD.
current study
Sensitivity of Imaging Modalities
Consistent with previous data, 14 the findings in the current study showed an improvement in adenoma detection sensitivity from 40% to 70% with SPGR over standard SE MRI sequences. The sensitivity of 18 F-FDG hrPET was 40% for the detection of CD adenomas in the current series, which was less than the sensitivity (70%) of SPGR MRI techniques for detection of pituitary adenomas in this series of patients with CD. Similarly, previous studies reported an advantage of 18 F-FDG PET over SE MRI sequences, as we found in the current series.
1,4 Nevertheless, we found no advantage of 18 F-FDG hrPET over high-resolution SPGR MRI. These data underscore the effectiveness of SPGR MRI for detecting ACTH-secreting adenomas in CD.
Regardless of the imaging modality, when an adenoma was identified it corresponded with the location (side of gland) and size of the tumor. These findings indicate that methods to improve the sensitivity of either MRI or PET will not only assist in diagnosis but will have direct surgical implications. Specifically, any of these modalities, including 18 F-FDG hrPET, can guide surgical exploration (and perhaps partial hypophysectomy) to the correct location within the pituitary gland and enhance effectiveness of resection. This is particularly important for very small (2 mm in diameter or less) imaging-invisible CD-associated adenomas that have not formed a pseudocapsule 6 and may be difficult to distinguish from normal pituitary gland.
Biological Implications
Previous studies in CD have not detected an association with biochemical markers for ACTH-secreting adenomas and 18 F-FDG uptake using standard-resolution PET imaging. 1, 4 Similar to De Souza colleagues 4 (who used standard-resolution PET imaging), we did not find an association between IPSS findings and 18 F-FDG uptake. Like- F-FDG hrPET-negative adenomas (Fig. 3) . Adenomas that have increased constitutive overexpression of ACTH and increased glucose uptake may have an attenuated response to CRH stimulation (i.e., less responsive to CRH stimulation). 
clinical implications
The findings of the current study demonstrate that the biochemical phenotype of CD-associated adenomas plays the largest role in 18 F-FDG PET positivity. Specifically, biological aspects have a larger role than adenoma size or dural invasion in determining 18 F-FDG uptake. These findings are supported by preoperative biochemical findings and the detection of very small adenomas (3 mm in diameter) by 18 F-FDG hrPET imaging but lack of detection of larger and more CRH stimulation responsive adenomas. Consequently, it is possible that biological features can be exploited to apply 18 F-FDG hrPET imaging in cases with comparatively blunted responses to CRH stimulation (less than 180% increase of ACTH; Fig. 3 ) and high midnight ACTH levels that do not have evidence of an adenoma on SPGR MRI. In such circumstances, it is possible that 
